GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio, Inc. Common Stock

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

National Science Foundation

GRI Bio, Inc.

Our CEO, Dr. Marc Hertz, highlights our novel approach to #immunemodulation. Watch the full video here: https://bit.ly/3FvbDJn  

#NKT #AutoimmuneDisease #InflammatoryDisease #FibroticDisease

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/3GvZu7M 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

Access our library of scientific publications for a comprehensive review of our data. https://bit.ly/3OhuOf8  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

#WhatThisMeans: Drs. Marc Hertz and Al Agro, CEO and CMO of GRI Bio, Inc., highlight the Company’s recent IND clearance for lead program targeting #idiopathicpulmonaryfibrosis. 

https://lnkd.in/eUEkB7DC
#IPF #NKT #FibroticDisease

GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant #NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/47we2Qm 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

We hope your Thanksgiving table is full of your favorite food and surrounded by your favorite people.

Regulating #NKT cells is a selective approach to #immunomodulation via resetting the immune response. Learn more here: https://bit.ly/3pRUJAu  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

GRI Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update.

https://bit.ly/47ce5kt 
#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

Email alerts make it easy to stay up to date! Sign up here: https://bit.ly/45GwuVq  

#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

We are dedicated to advancing new therapies through innovative approaches for the treatment of #inflammatory, #fibrotic and #autoimmune diseases. 

#NKT

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover		0.10 -
cash per share	117.81 -	3.36 97.15%	0.03 99.09%	0.00 90%	3.92 128,602.53%
company equity multiplier	1.33 -	-0.66 149.37%	-0.05 92.97%	-0.24 410.74%	11.41 4,942.38%
days of inventory outstanding
days of payables outstanding	122.33K -				9.03K -
days of sales outstanding
dividend yield
ebit per revenue		-47.88 -
ebt per ebit	1.10 -	1.01 8.30%	1.47 45.76%	1.44 2.12%	1.14 20.32%
effective tax rate	-0.00 -		0.03 -	-0.10 415.00%
enterprise value multiple	0.61 -	-10.92 1,901.88%	-527.17 4,729.54%	-12.06 97.71%	0.05 100.40%
fixed asset turnover		0.36 -
free cash flow per share	-88.91 -	-114.33 28.58%	-0.29 99.75%	-0.37 28.45%	-19.82 5,286.77%
gross profit margin		1 -
interest coverage	-16.01 -	-140.82 779.59%	-1.94 98.62%	-3.43 76.61%	-5.47 59.51%
inventory turnover
long term debt to capitalization		-0.01 -	-0.01 47.98%	-0.01 39.60%
net income per ebt	1 -	1 0%	0.97 3.21%	1.10 13.75%	1 9.18%
net profit margin		-48.22 -
operating cash flow per share	-88.91 -	-114.27 28.51%	-0.29 99.75%	-0.37 28.10%	-19.80 5,296.94%
operating profit margin		-47.88 -
payables turnover	0.00 -				0.04 -
pretax profit margin		-48.22 -
price fair value	0.49 -	-35.23 7,308.87%	-112.30 218.80%	-15.83 85.90%	4.79 130.28%
receivables turnover
return on assets	-0.81 -	-5.05 523.14%	-6.92 37.09%	-9.25 33.60%	-4.41 52.31%
return on capital employed	-0.91 -	3.77 514.51%	0.23 93.95%	1.39 509.45%	-43.97 3,263.38%
return on equity	-1.08 -	3.32 407.64%	0.32 90.37%	2.18 582.36%	-50.34 2,409.31%
total debt to capitalization	0.03 -	-0.13 596.40%	-3.26 2,426.23%	-0.71 78.29%	0.05 107.25%

COM:GRIBIO

GRI Bio, Inc.

Last Close

1.27

26/07 20:00

Market Cap

1.59M

Beta: -

Volume Today

457.28K

Avg: -

Preview